UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo UK Medical Research Logo Leeds University Logo Liverpool University Logo Newcastle University Logo Sheffield University Logo
UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo

Leeds Liverpool Newcastle Sheffield

MRC DiMeN Doctoral Training Partnership

Discovery Medicine North

Current Opportunities

Thank you for your interest in DiMeN DTP PhD studentships, applications for October 2019 entry have now closed. 


In this round, 32 studentships will be fully-funded based on student choice following candidate interviews.  For those of you who have submitted an application, please refer to the "Application overview" and "Eligibility" pages for more information on the selection process.



For information only: Project titles for Oct 2019 entry:                            

2. Developing non-invasive imaging strategies to investigate the effect of kidney disease on cardiovascular health and assess the ameliorative effect of a regenerative medicine therapy    (Liverpool: iCASE industry partner: Nano Biosols)

3. From cells to mind: Relational neurons and computations creating mental structures crucial for learning and memory   (Newcastle/iCASE industry partner: Rogue Resolutions)

4. Optogenetic programming of inflammation - in vivo Opto-GPCR approaches in neutrophils   (Sheffield)

5. Discovering the neuronal signalling mechanism at the heart of cardiac arrhythmias   (Leeds:  iCASE Industry partner: Badrilla Ltd)

6. The in situ 3D molecular structure of Alzheimer’s disease-associated pathology (Leeds)

10. The role of RNAseH2 in DNA repair and  diseases of aging   (Sheffield) 

11. Understanding asymmetric cell divisions at the onset of life   (Newcastle)

15. Mining the human gut microbiome for novel medically relevant glycoenzymes   (Newcastle)

17. Determining how post-transcriptional control of mRNA turnover and translation contributes towards age-associated joint diseases   (Liverpool)

18. Detection of ultra-low frequency heart rate variability markers of disease using AI beat detection and HRV modelling (Liverpool)

19. Development of deubiquitylase (DUB) inhibitors to target interferon-mediated diseases  (Leeds)

22. Mechanical activation of TGFbeta signaling in arterial disease   (Sheffield)

24. Building integrated machine learning and genomic approaches to quantitate bone quality and fracture risk   (Sheffield)

26. Magnetic resonance imaging of lung fibrosis in interstial lung disease – physics or engineering PhD project   (Sheffield:  Industry partner: Galapagos)

31. Integrated system for rigorous personalised diagnosis for Giant Cell Arteritis (GCA) with imaging and biopsy tests   (Liverpool)

32. Using bioinformatics to identify pathways regulating pancreatic beta-cell function and survival   (Newcastle/A*STAR: Singapore)

33. Waking up to neurodegenerative diseases: development of an awake mouse preparation to investigate neurovascular dysfunction in ageing and Alzheimer’s disease   (Sheffield)

35. New treatments for antimicrobial TB via modulation of innate immunity    (Sheffield) 

36. Application of data science to inherited genetic variants of apoptosis genes and susceptibility to breast cancer   (Sheffield)

37. Evolution of antimicrobial resistance in Clostridium difficile   (Sheffield)

41. Role of GPNMB in susceptibility to influenza virus infection: friend or foe?   (Liverpool)

43. Determination of how killer pathogenic fungi evade human innate immune defences   (Newcastle)

45. Functional Characterization of a Truncation Mutation Associated with Intellectual Disability    (Leeds)

48. A personalised model of coronary artery blood flow    (Sheffield)

49. Development of advanced MRI methods for measurement of pulmonary structural and functional change associated with lung disease    (Newcastle)

52. Defining the link between glucose,  miRNAs and extracellular vesicles in pregnancies complicated by maternal diabetes   (Leeds)

53. Addressing antimicrobial resistance (AMR): Affimers as therapeutic candidates and tools in antibacterial drug discovery   (Leeds. Collaborator/Industry sponsor: Public Health England)  

54. Identifying inhibitors specific to the OPG-kinome: towards novel treatments for Pulmonary Arterial Hypertension (PAH)    (Leeds)

56. Understanding the genetics of melanoma by studying heritable risk factors    (Leeds)

57. Capturing how Hsp90 prevents the formation of cell-disruptive toxic amyloid species by Cryo-EM in a C. elegans model for Alzheimer’s Disease   (Leeds)

58. Use of engineered protein polymers in wound repair   (Newcastle)

59. Proteomics approaches to discover new roles for non-canonical signalling in cancer   (Liverpool) 

60. Development and application of fast Magnetic Resonance Spectroscopic Imaging methods for neuro-chemical profiling   (Leeds)

61. How do neurodegenerative mutations in kinesin-1 alter its structure, motility and cellular function?   (Sheffield)

63. Developing novel therapies for babies born with univentricular hearts   (Newcastle)

65. Why do multiple pathogenic viruses including HIV, Influenza, Ebola, Herpesviruses and Adenovirus target the cellular transcription machinery?    (Sheffield) 

66. Mass spectrometry analysis of human tissue to characterise cleavage events resulting in amyloid deposition associated with aortic aneurysm and dissection    (Liverpool)

67. Antiretroviral-induced metabolic toxicity: Role of adipose-miRNAs as mechanistic regulators and toxicity biomarkers   (Liverpool)

68. Breaking up the fight: Defining the spatial requirements for therapeutic modulation of signaling through FcγRIIa   (Leeds)

72. Dissecting INPP5K function: cell biology, structural determination by X-ray crystallography and enzymology of a key protein implicated in muscular dystrophy, insulin signalling, spastic paraplegias and Parkinsonism   (Liverpool)

Any questions regarding DiMeN please contact the DTP manager Emily: